JPRN-UMIN000011147尚未招募未知
The exploratory study to determine optimum dosing of Axitinib (tyrosine kinase inhibitor) with pharmacokinetic analysis for patients with metastatic renal cell carcinoma - The study to determine optimum dosing of Axitinib for patients with metastatic renal cell carcinoma
Department of Urology, Graduate School of Medicine, Yamaguchi University0 个研究点目标入组 20 人开始时间: 2013年7月10日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) ECOG PS>1 2) sBP>150mmHg or dBP>100mmHg 3) Hb<9.0g/dl 4) neutrophil count<1000/mm3 5) pletelet count<75000/mm3 6) AST/ALT>2.5 ULN 7) total bilirubin>1.5 ULN 8) urine protein>2+ and 2g/day 9) sCre>1.5
研究者
相似试验
招募中
1 期
Dose finding study for deciding the optimal dose of fluorescein during probe based confocal endomicroscopyJPRN-UMIN000027696ational Cancer Center Hospital24
尚未招募
不适用
A clinical study to determine the optimal dose of WIN-1001X by evaluating its efficacy and safety in patients with early Parkinson’s diseaseDiseases of the nervous systemKCT0004536Medihelpline188
进行中（未招募）
1 期
A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis PatientsModerate to Severe left-sided Active Ulcerative ColitisEUCTR2016-004217-26-HUInDex Pharmaceuticals AB215
进行中（未招募）
1 期
A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis PatientsModerate to Severe left-sided Active Ulcerative ColitisEUCTR2016-004217-26-SEInDex Pharmaceuticals AB215
进行中（未招募）
1 期
A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis PatientsEUCTR2016-004217-26-ITINDEX PHARMACEUTICALS AB215